OCT2 expression in histiocytoses

Ungureanu, Irena Antonia; Cohen‐Aubart, Fleur; Héritier, Sébastien; Fraïtag, Sylvie; Charlotte, F.; Lequain, Hippolyte; Hélias‐Rodzewicz, Zofia; Haroche, Julien; Donadieu, Jean; Emile, Jean François

doi:10.1007/s00428-023-03508-7

Cited by 5 publications

(3 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the staining is sometimes of low intensity and its expression is mainly limited to RDD cases, although some other types of histiocytosis and some histiocytic sarcomas can also be positive. [18][19][20] On all our samples, the staining with PU.1 of tumour cells was either strong or completely absent (depending on the diagnosis), without cases of intermediate/weak staining, even on slides cut several weeks earlier (not shown). As PU.1 is also a B-lymphocyte marker, some cases required to stain another slide with PAX5 to exclude a B-cell proliferation.…”

Section: Discussionmentioning

confidence: 69%

“…OCT2 is another nuclear marker, which is expressed in B‐lymphocytes, in B‐cell lymphomas, and in some anaplastic large cell lymphomas, 17 was also reported to be positive in some histiocytoses. However, the staining is sometimes of low intensity and its expression is mainly limited to RDD cases, although some other types of histiocytosis and some histiocytic sarcomas can also be positive 18–20 . On all our samples, the staining with PU.1 of tumour cells was either strong or completely absent (depending on the diagnosis), without cases of intermediate/weak staining, even on slides cut several weeks earlier (not shown).…”

Section: Discussionmentioning

confidence: 70%

See 1 more Smart Citation

PU.1 is a useful nuclear marker to distinguish between histiocytosis and histiocyte‐rich tumours

et al. 2023

Self Cite

View full text Add to dashboard Cite

Aims The aim was to test the expression of PU.1 on different types of histiocytoses and to test the utility of PU.1 in confirming or excluding a histiocytic origin in tumour samples with suspicion of histiocytosis. Methods and Results We analysed 66 biopsies of nonmalignant histiocytoses represented by Langerhans‐cell histiocytosis (n = 13), Erdheim–Chester disease (ECD) (n = 19), Rosai–Dorfman disease (RDD) (n = 14), mixed ECD‐RDD (n = 3), ALK‐positive histiocytosis (n = 6), and juvenile xanthogranuloma (n = 11). All cases were positive for PU.1 in reactive and neoplastic histiocytes. In addition, 39 cases of tumours with high‐grade cytological atypia were referred to our center as suspicion of malignant histiocytosis/histiocytic sarcoma and only 18 were confirmed. Indeed, more than half of these tumours (21/39) were either undifferentiated malignant tumours with a stroma rich in histiocytes, diffuse large B‐cell lymphoma, or high‐grade dedifferentiated liposarcoma. PU.1 was useful to distinguish between the negativity of large atypical nuclei and the positivity of stromal reactive histiocytes. Conclusion PU.1 is expressed by all types of histiocytosis. It distinguishes histiocytosis from histiocyte‐rich tumours with an easy interpretation due to its sharp nuclear staining. Its negativity in lesional/tumour cells in histiocyte‐like lesions is useful to eliminate a histiocytosis.

show abstract

Section: Discussionmentioning

confidence: 69%

Section: Discussionmentioning

confidence: 70%

PU.1 is a useful nuclear marker to distinguish between histiocytosis and histiocyte‐rich tumours

et al. 2023

Self Cite

View full text Add to dashboard Cite

show abstract

“…Immunostaining for OCT2, a highly sensitive marker for RDD 4,5 , showed crisp nuclear marking in the neoplastic cells (Fig. 2F), con rming the diagnosis of testicular RDD.…”

Section: Case Presentationmentioning

confidence: 70%

Testicular Rosai-Dorfman disease clonally related to CMML – case report and literature review

Fiegl

Dirnhofer

Juškevičius

et al. 2023

Preprint

View full text Add to dashboard Cite

Background: Rosai-Dorfman disease (RDD), a rare form of non-Langerhans cell histiocytosis with heterogenous clinical features, arises from precursor cells that give rise to cells of the histiocytic and monocytic lineages. An association with hematological neoplasms has been reported. Testicular RDD is rarely described, with only 9 reported cases in the literature. Genetic data to assess clonal relationships between RDD and other hematological neoplasms remain scarce. We describe an instance of testicular RDD against a background of chronic myelomonocytic leukemia (CMML), with genetic studies in both neoplasms. Case presentation: A 72-year-old patient with a history of CMML sought evaluation of growing bilateral testicular nodules. Solitary testicular lymphoma was suspected; orchidectomy was performed. The diagnosis of testicular RDD was established morphologically and confirmed immunohistochemically. Molecular analysis of testicular lesions and of archived patient bone marrow revealed the KRAS variant c.35G>A / p.G12D in both, suggesting a clonal relationship. Conclusion: These observations support classifying RDD as a neoplasm that can be clonally related to myeloid neoplasms.

show abstract

Fifth Edition of the World Health Organization Classification of Tumors of the Hematopoietic and Lymphoid Tissues: Acute Lymphoblastic Leukemias, Mixed-Phenotype Acute Leukemias, Myeloid/Lymphoid Neoplasms With Eosinophilia, Dendritic/Histiocytic Neoplasms, and Genetic Tumor Syndromes

Choi,

Xiao,

Chen

et al. 2024

Modern Pathology

View full text Add to dashboard Cite

OCT2 expression in histiocytoses

Cited by 5 publications

References 21 publications

PU.1 is a useful nuclear marker to distinguish between histiocytosis and histiocyte‐rich tumours

PU.1 is a useful nuclear marker to distinguish between histiocytosis and histiocyte‐rich tumours

Testicular Rosai-Dorfman disease clonally related to CMML – case report and literature review

Fifth Edition of the World Health Organization Classification of Tumors of the Hematopoietic and Lymphoid Tissues: Acute Lymphoblastic Leukemias, Mixed-Phenotype Acute Leukemias, Myeloid/Lymphoid Neoplasms With Eosinophilia, Dendritic/Histiocytic Neoplasms, and Genetic Tumor Syndromes

Contact Info

Product

Resources

About